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a b s t r a c t
Wilson's disease (WD) is caused by excess of copper that leads to accumulation of copper
mainly in the liver, brain and needs life-long decoppering therapy. However, overtreatment
with anti-copper agents may lead to copper deﬁciency which may cause neurological and
hematological symptoms. Copper is an important cofactor for many enzymes. This report
describes three WD patients with diagnosed copper deﬁciency during zinc sulphate (ZS)
treatment. After 5–16 years of therapy all patients developed leucopenia. Spinal cord injury
was manifested in two of the patients. One of them also presented myopathy. In conclusion,
copper deﬁciency may occur in different time after treatment onset, therefore regular copper
metabolism and hematological monitoring is necessary.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Wilson's disease (WD) is an inherited copper metabolism
disease that leads to accumulation of copper in the liver, brain,
cornea, and other organs. The clinical course of WD may be
highly variable and includes hepatic, neurological, and
psychiatric symptoms [1,2]. WD is an autosomal recessive
disorder caused by mutation of the ATP7B gene on chromo-
some 13 [3], which encodes a copper-transporting P-type
ATPase [4]. The aim of WD treatment is to remove excess of
copper and prevent its re-accumulation [5,6]. There are two
different therapeutic approaches in WD. The ﬁrst group of
drugs (d-penicillamine, trientine) are chelating agents which* Corresponding author at: Institute of Psychiatry and Neurology, Secon
Tel.: +48 22 4582537; fax: +48 22 8424023.
E-mail address: czlonkow@ipin.edu.pl (A. Członkowska).
http://dx.doi.org/10.1016/j.pjnns.2014.05.002
0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Uact by promoting the urinary excretion of copper. The second
group (zinc salts) interfere with intestinal uptake of copper
[7,8].
Clinical symptoms of WD are caused by excess of copper.
However, copper is needed because it acts as important
cofactor for many important enzymes that have a role in
functioning of the nervous system including cytochrome-c
oxidase, copper-zinc superoxide dismutase, and dopamine b-
hydroxylase [9].
Possible causes of copper deﬁciency include hereditary
conditions such as Menkes Disease and acquired causes:
malnutrition, parenteral or enteral feeding without copper
supplementation, gastrectomy, proximal bowel resection,
over-treatment by zinc salts or copper chelating agent [10].d Department of Neurology, Sobieskiego 9, 02-957 Warsaw, Poland.
rban & Partner Sp. z o.o. All rights reserved.
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mia, neutropenia, thrombocytopenia) and neurological (axo-
nal neuropathy, myelopathy, posterior spinal column
dysfunction, central nervous system demyelination, myop-
athy) signs. MRI ﬁndings include changes in dorsal columns
of spinal cord radiologically similar to those caused by
vitamin B12 deﬁciency and demyelination lesions in brain
[10–17]. Electrophysiological studies may indicate axonal
neuropathy, central conduction delay in somatosensory
pathways, prolonged visual evoked potentials, myopathic
changes [17,18].
Copper deﬁciency in WD may be caused by too excessive
treatment with anti-copper agents. We report three patients
with WD who were diagnosed with copper deﬁciency during
zinc sulphate (ZS) treatment.
2. Case reports
2.1. Patient 1
A 37-year-old woman with WD diagnosed 16 years ago and
since then treated with anti-copper agent. She complained of
paraesthesias in the ﬁngers and toes for 3 months and she felt
weakness of the lower limbs during fast walking over the past
1 month. She was diagnosed in presymtomatic phase of the
disease (without hepatic, neurologic signs, no Kayser–
Fleischer rings). Diagnosis was conﬁrmed by genetic studies.
Her brother was a proband. Since diagnosis she was taking ZS
in daily dose 180 mg of elementary zinc. She regularly visited
our clinic and earlier she had never had neurological
symptoms. Hematological tests were always normal. Copper
metabolism did not indicate overtreatment. Additionally,
laboratory test results had revealed leucopenia 1 month
before symptoms started (Table 1).
On admission to our clinic her neurological examination
was normal. Copper metabolism test results showed very low
concentration of serum ceruloplasmin and serum copper.
Copper urinary excretion was also low. Zinc serum concen-
tration was very high (Table 1). Somatosensory evoked
potentials (SEPs) showed impaired conduction in the dorsal
column, especially in thoracic spine. Nerve conduction studies
were within normal limits. Electromyography (EMG) was
suggestive of myopathy. A few low-amplitude, short duration
motor units were noted. There was no denervation and
recruitment was normal. MRI of cervical spine, showed linear
increased T2 signal lesion in the posterior column of the
cervical cord from C2 to C7-Th1 (Fig. 1A and C). Brain MRI was
normal.
Vitamin B12 level was in normal range. We recognized
copper deﬁciency. Liver tests results were normal, so we
decided to withdraw ZS to increase serum copper concentra-
tion. After one month white cell blood count was normal.
Follow-up copper metabolism test results showed increase
serum ceruloplasmin concentration (5 mg/dl) and serum
copper concentration (20 mg/dl). She did not report lower
limbs weakness and paraesthesias in the ﬁngers and toes were
less pronounced. MRI of cervical spine showed marked
diminished dorsal columns compared to previous examina-
tion (Fig. 1B and D). On the second examination myopathic
Fig. 1 – (A) Sagittal T2-weighted MRI of the cervical spine: linear increased T2 signal (arrow) in the posterior surface of the
cervical cord from C2 to C7-Th1 (March 2013) and follow-up MRI, (B) without evident changes (October 2013), (C) axial T2-
weighted image shows the signal hyperintensity (arrows) located symmetrically in the dorsal columns and follow-up MRI
with slightly hyperintensity signal in dorsal column (D).
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 2 1 4 – 2 1 8216changes on EMG normalized, however SEPs still indicated
abnormalities in the dorsal column.
Nine months after interruption in anti-copper treatment
after clinical and laboratory improvement, we decided to
introduce d-penicillamine instead of ZS.
2.2. Patient 2
A 46-year-old woman diagnosed with WD 5 years ago. She
started to have recurrent upper respiratory tract infections for
the last 6 months. At WD diagnosis she had liver failure and
typical for WD biochemical changes (Table 1). Diagnosis was
conﬁrmed by genetic studies. She was taking zinc sulphate
(180 Zn of elementary zinc daily). Liver function markedlyimproved. Regular hematological tests were normal. Copper
metabolism parameters did not indicate overtreatment.
Due to respiratory infections she had basic laboratory tests
done which indicated leucopenia with neutropenia (Table 1).
We also found signiﬁcant, in comparison with previous
results, decrease of serum ceruloplasmin concentration
(0.5 mg/dl) and serum copper (<5 mg/dl) suggesting copper
deﬁciency during WD overtreatment (Table 1). SEPs were
within normal limits. We decided to decrease the dose of zinc
sulphate to 135 mg/24 h. Her hematology parameters im-
proved and the patient did not report any infections. Follow-up
copper metabolism tests results showed increased level of
serum ceruloplasmin 1.18 mg/dl, but still low serum copper
concentration (5 mg/dl). We decided to treat this patient
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 2 1 4 – 2 1 8 217chronically with lower dose of ZS (135 mg elementary zinc)
with regular monitoring of copper metabolism parameters.
2.3. Patient 3
A 18-year-old woman with presymptomatic WD diagnosed 6
years ago, was admitted to our clinic because of leucopenia
with neutropenia and anemia (Table 1). Before admission to
our clinic she had diagnostics in hematology center. A bone
marrow biopsy was performed. Myelodysplastic syndromes
and aplasia were excluded. It was suggested that hematologi-
cal signs are caused by anti-copper treatment.
She has never presented any WD symptoms. Her mother
was diagnosed with neurologic form of WD disease. The WD
diagnosis was conﬁrmed by biochemical tests result (Table 1)
and radiocopper study was used. Since diagnosis she was
treated with ZS in daily dose 180 mg. On admission to our
clinic her neurological examination was normal. Copper
metabolism test results showed very low serum ceruloplasmin
concentration, copper serum concentration and low copper
urinary copper excretion (Table 1). Brain MRI did not show
typical of WD changes. SEPs showed impaired conduction in
the dorsal column. Nerve conduction studies were within
normal limits. The patient refused to undergo MRI of cervical
spine. Vitamin B12 level, folic acid, liver tests results was in
normal range. We decided to withdraw ZS and after two
months white cell blood count was normal. Follow-up copper
metabolism test results showed higher concentration of
serum ceruloplasmin and serum copper. However, urinary
copper excretion was still very low and we decided to leave the
patient without anti-copper treatment for longer period
(Table 1).
3. Discussion
All 3 described patients were treated with Zn for 5–16 years and
had clinical and laboratory signs suggestive of copper
deﬁciency.
Copper deﬁciency in WD has been reported in few patients
so far. First reported patient in 1989 with hematologic signs
was treated with high zinc salts doses (275 mg of elementary
zinc) [19]. Recently, 6 other WD patients with neurological
symptoms of copper deﬁciency were reported. They presented
axonal neuropathy (n = 3), myeloneuropathy (n = 1), myelopa-
thy (n = 1) and CNS demyelination (n = 1). One of them also
presented kidneys involvement. Three of those reported
patients were on zinc monotherapy. Two of them were treated
with very high daily doses (275 mg of elementary zinc). The
others were treated with combination of d-penicylamine or
trientine and zinc salts [20–25].
Our patients were treated with standard doses of ZS
(180 mg of elementary Zn2+) in monotherapy. All of
them were regularly monitored with copper metabolism
parameters and basic laboratory tests. Two of them had
presymptomatic form of WD. All previously reported
cases were symptomatic. All had leucopenia which may
be seen in course of WD [26]. However, all presented
patients had normal hematological tests at the time of
diagnosis. Myelopathy together with myopathic changes inelectromyography were not to our knowledge reported in WD
patient with copper-deﬁciency before. However, myopathy
was reported as possible sign in copper deﬁciency [17]. These
myogenic changes in our patient disappeared after 6 months
in treatment disruption.
High zinc concentration may cause copper deﬁciency
because during zinc therapy intestinal absorption of copper
decreases. Zinc induces concentration of metallothionein in
enterocytes. Copper has higher afﬁnity for metallothionein
than zinc and displaces zinc from metallothionein. Then
copper is sloughed off into the intestinal tract [13].
In our patients we examined total serum copper
concentration, which is decreased in WD. Toxic free copper
concentration may be calculated from total serum copper
concentration and serum ceruloplasmin concentration [5].
Calculated free copper concentration in our patients is very
low (<5 mg/dl) as well as serum copper concentration
(<1 mg/dl) .The precise method is direct measurement of
free blood copper concentration [27]. More recent, relative
exchangeable copper (REC) was demonstrated as accurate
tool to determine fraction of free blood copper concentration
[28].
According to European and American recommendations on
WD treatment monitoring of therapy should be regular. At
least twice per year and more frequent at the beginning of
therapy. Treatment monitoring should include copper metab-
olism parameters (serum copper and ceruloplasmin concen-
tration, urinary copper excretion) as well as liver function
parameters and complete blood count. By measuring the
serum non-ceruloplasmin (free copper) bound copper concen-
tration we may assess treatment efﬁcacy. In inadequately
treated patients it is usually above 25 mg/dl (normal range 10–
15 mg/dl). In case of overtreatment the values are very low
(<5 mg/dl). Additionally, in patient treated with d-penicilla-
mine urinary copper excretion should be between 200 and
500 mg/24 h and for patients on zinc it should be below 75 mg/
24 h [5,8,29].
4. Conclusion
Overtreatment with zinc salts may cause deﬁciency of
copper with hematologic and neurologic symptoms. Our
cases show that regular monitoring of copper metabolism
tests and blood count cells is very important for safety
treatment with zinc salts and early recognition of copper
deﬁciency. Patients should be under care of center experi-
enced in monitoring anti-copper treatment for proper
analysis of copper metabolism parameters to avoid such
treatment complication.
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